palmitoyl hexapeptide-12
Pal-VGVAPG, N-palmitoyl-Val-Gly-Val-Ala-Pro-Gly, palmitoylated elastin hexapeptide
Palmitoyl hexapeptide-12 is the tropoelastin repeat motif Val-Gly-Val-Ala-Pro-Gly with a palmitic acid chain attached. VGVAPG is the best-characterised of all elastin-derived peptides, but the published biology of this elastokine is substantially about matrix degradation, inflammation and cell proliferation, which makes it a more double-edged cosmetic ingredient than its 'elastin support' positioning suggests.
Mechanism
VGVAPG is a hydrophobic repeat present in multiple copies in mammalian tropoelastin and released when elastin is degraded by elastases during ageing, ultraviolet exposure and inflammation. It is the canonical ligand of the elastin receptor complex, assembled around the elastin-binding protein (a 67 kDa, catalytically inactive, alternatively spliced variant of beta-galactosidase) in association with neuraminidase-1 and protective protein/cathepsin A. Mecham and colleagues characterised the 67 kDa elastin-binding protein in 1989, Grosso and Scott established that VGVAPG-type sequences are its ligands, and Blanchevoye and colleagues later characterised the VGVAPG-elastin-binding protein interaction in detail, including its conformational requirements.
Engagement of this receptor triggers ERK1/2 signalling and a set of downstream responses that are well documented and, from a skincare standpoint, mixed. Elastin-derived peptides containing this motif are chemotactic for fibroblasts and monocytes, promote proliferation of fibroblasts and of melanoma cells, and upregulate matrix metalloproteinase-1 and matrix metalloproteinase-2. Brassart and colleagues showed that MMP-1 upregulation by elastin peptides depends on their conformation, meaning the effect is a specific receptor-mediated signal rather than an artefact. This is the pharmacology of an alarm signal generated when elastin is being destroyed, not of a building block, and elastokines of this family have been implicated in photoageing, emphysema and tumour invasion. Palmitoylation adds lipophilicity for stratum corneum partitioning; Ligorio and colleagues showed in 2025 that the palmitoylated peptide permeates stratum corneum and epidermis, initiates gel formation by harnessing endogenous ions, co-assembles with native skin molecules, and strengthens and repairs barrier function after delipidation.
What the research shows
The elastin receptor literature is consistent and replicated. Mecham and colleagues identified the 67 kDa peripheral membrane protein that binds elastin; Grosso and Scott showed that VGVAPG-family sequences selected by a tropoelastin-specific monoclonal antibody are its ligands; Blanchevoye and colleagues dissected the VGVAPG-elastin-binding protein interaction and its conformational requirements. Functionally, Brassart and colleagues demonstrated conformation-dependent upregulation of collagenase (MMP-1) by elastin peptides in cultured fibroblasts, and Chatron-Colliet and colleagues showed that a VGVAPG trimer reorganises nuclear architecture and accelerates proliferation of both fibroblasts and melanoma cells.
For the cosmetic ingredient specifically, the important contribution is Ligorio and colleagues in ACS Applied Bio Materials, who used orbital trapping secondary ion mass spectrometry to distinguish sol and gel forms of the peptide and track its self-assembly and penetration in full-thickness human skin, with high-throughput mechanical characterisation and stimulated Raman scattering showing barrier strengthening and repair after delipidation, and in vitro and ex vivo histology showing co-assembly with native skin molecules. This is a serious piece of analytical work and it establishes something most cosmetic peptides cannot claim: that the molecule gets in. It also attributes the benefit to self-assembly and mechanical interaction rather than to elastin receptor signalling, which may be the more defensible way to think about the ingredient. There is no clinical trial data.
Evidence assessment
Preclinical only
There is no randomised controlled trial and no published human efficacy study of palmitoyl hexapeptide-12; a PubMed phrase search returns exactly one record, the Ligorio 2025 analytical paper. What exists is an unusually good preclinical and biophysical record: three decades of elastin receptor biology for the peptide motif, plus a study that tracked the palmitoylated ingredient itself through full-thickness human skin and characterised its self-assembly and mechanical effects. That paper is genuine ex vivo human tissue work, but it measures penetration and mechanics rather than clinical benefit, and it was co-authored by a cosmetics manufacturer's research division alongside two university groups. Preclinical is therefore the right tier, with the qualification that the preclinical literature contains findings that complicate rather than support the cosmetic rationale.
Tiers are applied consistently across the library and re-checked when new trials read out. Read the grading method.
Key studies
Elastin binds to a multifunctional 67-kilodalton peripheral membrane protein Preclinical only
Identified the 67 kDa elastin-binding protein, the core of the elastin receptor complex through which VGVAPG signals.
Peptide sequences selected by BA4, a tropoelastin-specific monoclonal antibody, are ligands for the 67-kilodalton bovine elastin receptor Preclinical only
Established VGVAPG-family sequences as ligands for the 67 kDa elastin receptor.
Conformational dependence of collagenase (matrix metalloproteinase-1) up-regulation by elastin peptides in cultured fibroblasts Preclinical only
Elastin peptides upregulated MMP-1 in a conformation-dependent manner, confirming a specific receptor-mediated pro-proteolytic signal rather than a non-specific effect.
Interaction between the elastin peptide VGVAPG and human elastin binding protein Preclinical only
Characterised the VGVAPG interaction with human elastin-binding protein in detail, including its conformational requirements.
The elastin peptide (VGVAPG)3 induces the 3D reorganisation of PML-NBs and SC35 speckles architecture, and accelerates proliferation of fibroblasts and melanoma cells Preclinical only
A VGVAPG trimer reorganised nuclear body architecture and accelerated proliferation of both fibroblasts and melanoma cells.
Noninvasive Monitoring of Palmitoyl Hexapeptide-12 in Human Skin Layers: Mechanical Interaction with Skin Components and Its Potential Skincare Benefits Preclinical only
The palmitoylated peptide permeated stratum corneum and epidermis, initiated gel formation by harnessing endogenous ions, co-assembled with native skin molecules, and strengthened and repaired barrier function after delipidation.
Safety
No adverse effects have been reported from cosmetic use, and the peptide is non-irritating at typical concentrations. The honest safety discussion for this ingredient, however, is not about irritation. Elastin-derived peptides of the VGVAPG family are pro-inflammatory and pro-proteolytic signals in the published literature: they upregulate matrix metalloproteinases, are chemotactic for monocytes, and have been shown to accelerate proliferation of melanoma cells in culture. Elastokines are implicated in the pathophysiology of photoageing, emphysema and tumour cell invasion. None of this has been demonstrated to occur at cosmetic exposures in intact human skin, and no clinical harm has been reported, but a reader should know that the receptor this ingredient targets is one the body uses to signal that elastin is being destroyed. Anyone with a personal history of melanoma weighing an ingredient shown to accelerate melanoma cell proliferation in vitro has a reasonable question to raise with a dermatologist, even in the absence of clinical data. No reproductive, pregnancy or lactation data. Topical cosmetic ingredient only; not evaluated for injection.
Regulatory status
| Jurisdiction | Status |
|---|---|
| United Kingdom | Permitted as a cosmetic ingredient under the UK Cosmetics Regulation (retained Regulation (EC) No 1223/2009); not listed in any prohibited or restricted annex. Requires a Cosmetic Product Safety Report and responsible person. No MHRA medicines authorisation. |
| United States | Not an FDA-approved drug and not covered by an OTC drug monograph; marketed as a cosmetic ingredient under the FD&C Act as amended by the Modernization of Cosmetics Regulation Act 2022. Cosmetic ingredients are not pre-approved, but structure-or-function claims can render a product an unapproved drug. |
| WADA (sport) | Not named on the WADA Prohibited List. Topical cosmetic use raises no anti-doping issue. |
Questions
No published evidence supports that. VGVAPG is a fragment released when elastin is broken down, and its documented receptor signalling upregulates matrix metalloproteinases, is chemotactic for immune cells, and drives proliferation. It is better understood as an elastin degradation signal than as an elastin building block.
Yes, and unusually good evidence. A 2025 study used label-free mass spectrometry imaging and Raman scattering on full-thickness human skin to show the palmitoylated peptide entering the stratum corneum and epidermis and forming a gel in response to skin ions. That is more penetration evidence than most cosmetic peptides have.
The most defensible published benefit is mechanical rather than biochemical: the lipopeptide self-assembles with native skin molecules and strengthened and repaired barrier function in delipidated skin. That is a real finding, but it is a barrier and texture effect, not the elastin-restoring effect implied by the marketing.
It is worth knowing about rather than panicking over. A VGVAPG trimer accelerated proliferation of melanoma cells in culture, and elastokines of this family are implicated in tumour invasion in the research literature. No clinical harm has been reported from cosmetic use and the exposures are not comparable. Anyone with a personal history of melanoma can reasonably raise the ingredient with their dermatologist.